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it ponders how best to extend these services to larger
populations.
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Linkage Disequilibrium Analysis in a Recently
Founded Population: Evaluation of the Variegate
Porphyria Founder in South African Afrikaners
To the Editor:
Variegate porphyria (VP; MIM 176200) is relatively rare
in most populations, but it is one of the most common
autosomal dominant genetic disorders in South Africa
(Dean 1971). The disease is characterized by a diversity
of symptoms, including a variable picture of skin symp-
toms and acute attacks. By means of genealogical stud-
ies, the history of VP in South Africa can be traced back
to the marriage of a Dutch couple in the Cape of Good
Hope in 1688 (Dean 1971). This, along with the high
prevalence of VP in South Africa, has promoted the
founder-gene hypothesis for VP in this country.
Mutations in the protoporphyrinogen oxidase gene
(PPOX), the seventh enzyme in the heme biosynthetic
pathway, have been shown to be causative of VP (Dey-
bach et al. 1996; Meissner et al. 1996; Warnich et al.
1996b; Lam et al. 1997). This gene has been mapped
to chromosome 1q22 by FISH (Taketani et al. 1995),
and the position has been confirmed by linkage analysis
(Roberts et al. 1995). Three mutations have been de-
scribed in South African VP patients, but one of these,
a CrT transition at nucleotide position 452 (R59W),
was found in ∼90% of patients (Meissner et al. 1996;
Warnich et al. 1996b). This mutation spanned a CpG
dinucleotide, and, to exclude the possibility of a recur-
rent mutation, intragenic haplotype studies were under-
taken. Mutation R59Wwas shown to be associatedwith
one of four potential haplotypes defined by two diallelic
polymorphisms in exon 1 (Warnich et al. 1996b), thus
supporting the founder hypothesis. However, this was
not totally conclusive evidence, since the alleles associ-
ated with the R59W mutation are also the common al-
leles in the normal population for each of the polymor-
phisms (L. Warnich, unpublished data).
If the high incidence of a genetic disease in a particular
population is due to a founder effect, most cases studied
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Table 1
Allele Frequencies and LD Results for the Most Common Alleles of the 15 R59W-Mutation Chromosomes and for 88 Normal Chromosomes
DISTANCE TO NEXT
MARKER LOCUSa
(cM)
MARKER
LOCUS
FREQUENCY OF CHROMOSOME
x2 (P)d PexcessNormal
b Diseasec
D1S2140 .34 .47 .8805 (.3481) .1908
.7
D1S303 .60 .87 3.892 (.0485) .6648
.0
D1S1595 .18 .33 1.8126 (.1782) .1852
3.0
D1S1600 .17 .53 9.7301 (.0018) .4374
.0
D1S1653 .09 .53 19.1183 (!.0001) .4867
1.5
D1S398 .33 .53 2.3122 (.1284) .3040
2.8
D1S2707 .30 .93 21.2613 (!.0001) .9044
1.2
D1S484 .30 .93 21.9526 (!.0001) .9054
1.2
D1S2705 .28 .93 22.9604 (!.0001) .9069
.0
D1S1679 .16 .67 18.4746 (!.0001) .6036
4.8
D1S104 .18 .73 20.1534 (!.0001) .6741
.0
D1S1677 .38 .80 9.4091 (.0022) .6800
2.2
D1S426 .10 .53 17.2799 (!.0001) .4802
.6
ATA38A05 .15 .47 11.7399 (.0006) .4524
3.0
D1S196 .26
.30
.47
.47
2.6167 (.1057)
1.7253 (.1890)
.2779
.2430
a Obtained from the Ge´ne´thon and CHLC databases and from the sex-averaged map of the Marshfield Medical Research Foundation (http:
//www.marshmed.org/genetics/).
b Includes chromosomes from 27 individuals who were relatives of the families by marriage, as well as 34 normal chromosomes of affected
parents.
c Calculated by counting, with use of the oldest R59W-mutation chromosome in each family.
d Calculations for statistical significance of data were done for the most common allele of each marker, in a pairwise manner using the x2
test with 1 df and no correction (Dawson-Saunders and Trapp 1990, pp. 150–151).
should have preserved alleles at closely linked loci, pre-
senting the original founder chromosome (Ha¨stbacka et
al. 1992). In recently founded populations, comparable
to the South African Afrikaner population, a conserved
area of ∼5–20 cM can be expected (Houwen et al. 1994).
In the present study we have used linkage disequilibrium
(LD) and haplotype analyses to investigate the single-
founder hypothesis for VP in South Africa and to eval-
uate the use of the Afrikaner population for future LD
mapping studies.
In the current study, 15 nuclear families with the
R59W mutation (Warnich et al. 1996b, 1996c) were
extended to include 132 members, 58 of whom were
affected. The 15 families were unrelated to the second-
degree and included one four-generation, seven three-
generation, and seven two-generation pedigrees. A se-
quence-tagged site (STS) at the 3′ end of the PPOX gene
was used to screen the CEPH YAC libraries. The primers
used were D38537-F (5′-GGG AGT TGC TGT TAA
TGA CTG T-3) and D38537-R (5′-GCA ATT TTT ATT
TTC ATG AAT GAG-3′). One of the positive YAC
clones, 910C8, showed an unambiguous hit for two
microsatellite markers, D1S2705 and D1S484. Thirteen
other microsatellite markers flanking these markers
(listed in table 1) and spanning ∼21 cM, were subse-
quently selected from the Ge´ne´thon (http://
gdbwww.gdb.org) and Cooperative Human Linkage
Center (CHLC; http://www.chlc.org) databases.
Haplotypes were constructed in each family under the
assumption that there were the minimum number of
recombinations. Disease-associated haplotypes were
identified from alleles that were transmitted from af-
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Figure 1 Disease-associated haplotypes of each of the 15 families. The oldest R59W-mutation chromosome in each family was used. The
patterned sections indicate the regions conserved between the affected haplotypes of the different families.
fected parent to affected offspring, in each pedigree.
Crossover events on the disease-associated chromosomes
of two different individuals placed the PPOX gene telo-
meric of marker D1S2707 in one of them and centro-
meric of marker D1S2705 in the other. These observed
recombinations delimit the location of the PPOX gene
to a 2.4-cM region between markers D1S2705 and
D1S2707, and they thus represent the highest-resolution
genetic mapping of the gene yet.
LD studies were done by calculation of the statistical
factor Pexcess for the dominant disease-associated allele of
each marker (Hastba¨cka et al. 1992). The number of
generations since the introduction of the VP gene was
taken, on the basis of available genealogical records, as
12. The data generated are shown in table 1. The strong-
est association was observed at D1S2707 (allele 3),
D1S484 (allele 2), and D1S2705 (allele 4), yielding Pexcess
values of .9044, .9054, and .9069, respectively. Two-
point linkage analysis (data not shown) also illustrated
close linkage of the disease locus to these three markers,
with LOD scores of 9.37, 12.68, and 10.74 at recom-
bination fraction (v) values of .031, .023, and .014,
respectively.
The extended haplotype associated with the R59W
mutation in each family is shown in figure 1. Allele 3
was found to be conserved for marker D1S2707 in all
of the families with the R59W mutation, except family
B. Alleles 2 and 4 were detected for the markers D1S484
and D1S2705 in all of the families, except family L. Since
the latter two markers are the nearest to the gene, we
propose that family L most likely has an independent
R59W mutation. It could thus be deduced that a small
percentage of families with the R59Wmutation will rep-
resent either recurrent mutations at the CpG hot spot
or recent importations of the gene. It is interesting to
note that the haplotype of family L could not be distin-
guished from the haplotypes of the other families when
diallelic intragenic markers were used (Warnich et al.
1996a, 1996b). As shown in figure 1, two distinct sub-
haplotypes were observed surrounding the core haplo-
type—namely, the haplotype represented by families A,
P, G, M, and D and the haplotype depicted by families
B, K, J, E, C, O, N, H, and F. It is thus expected that
variations in these subhaplotypes can be ascribed to ear-
lier historical recombination events and/or mutations at
some loci. We thus believe that, although there are ap-
parently two groups of haplotypes that differ in flanking
markers, they both descend from the same founder, be-
cause they share the same core haplotype, as has also
been found in other founder-related studies (e.g., Labuda
et al. 1996). There is also no geographical or genealog-
ical evidence for two independent introductions of the
VP gene in South Africa. Furthermore, a contiguous area
of 10 cM (spanned by markers D1S2707 and
ATA38A05) displayed highly significant ( ) LDP ! .005
values (table 1). These results are in agreement with data
from other populations, in which the historical age of
the founder effect was estimated to be 12 (Labuda et al.
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1996), 8–12 (Puffenberger et al. 1994), and 5–12 gen-
erations (Houwen et al. 1994). In two other studies
based on South African families, a conserved region of
∼8 cM was found in two long-QT families with contin-
uing genealogical studies already extending back
through nine generations (de Jager et al. 1996), whereas
an ancestral haplotype of 11 cM was found in 11 of 14
South African families with keratolytic winter erythema
(Starfield et al. 1997).
Large shared segments are expected around disease
genes in recently founded populations such as the Af-
rikaner population, and it was thus predicted that ge-
nome searches for these segments could be performed
with only a few hundred markers (Houwen et al. 1994).
This potentially powerful approach of LD mapping has,
however, not been widely used in the past, one of the
reasons being the scarcity of suitable founder popula-
tions. The next phase of gene mapping—namely, the
mapping of complex traits—may especially benefit from
conserved-haplotype detection and LD mapping in iso-
lated populations (Lander and Schork 1994). Although
the Afrikaner population is known to have founder ef-
fects for a number of genetic disorders (Jenkins 1990),
it has rarely been exploited for the actual mapping of
genes in the past.
From the results of the present study we conclude that
the high frequency of the R59W mutation in South Af-
rica could probably be ascribed to a common ancestor
and is not due to multiple mutation events on a common
haplotype. The current study thus not only provides the
first firm molecular evidence for a founder hypothesis
for VP but also shows that the South African Afrikaner
population is a valuable candidate population for future
mapping studies using LD analyses.
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Worldwide Distribution of a Common
Methylenetetrahydrofolate Reductase Mutation
To the Editor:
Methylenetetrahydrofolate reductase (MTHFR) cata-
lyzes the reduction of 5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, which is needed for methio-
nine synthase to convert homocysteine to methionine. A
reduction in MTHFR activity, such as that caused by
the CrT missense mutation at position 677 of the
MTHFR cDNA (C677T), which produces a thermola-
bile form of the enzyme, results in increased plasma
homocysteine (Frosst et al. 1995). Homozygotes for the
C677T mutation may have an increased risk of cardio-
vascular disease (Frosst et al. 1995) and neural tube
defects (Wilcken 1997).
Folate is an important cofactor in the conversion of
homocysteine to methionine; therefore, C677T homo-
zygotes may require more folate for thermolabile
MTHFR to function adequately. Insufficient folate in-
take during pregnancy can cause neural tube defects
(Smithells et al. 1980); however, the role of folate in
vascular disease is not well established.
Previous studies of the C677T mutation have concen-
trated on European populations. The allele frequency in
Europeans is 24%–40% (van der Put et al. 1997),
26%–37% in Japanese populations (Papapetrou et al.
1997; Sohda et al. 1997), and ∼11% in an African Amer-
ican population (Stevenson et al. 1997). We have
screened 881 unrelated individuals from 16 worldwide
populations for the presence of the C677T polymor-
phism (table 1). The populations studied were chosen
to complement the existing data set of the worldwide
C677T allele frequency. The samples used in this study
are anonymous and have been collected for ongoing
studies of human genetic diversity. New primers used in
this study (forward: 5′-TTT GAG GCT GAC CTG AAG
CAC TTG AAG GAG-3′; and reverse: 5′-GAG TGG
TAG CCC TGG ATG GGA AAG ATC CCG-3′) gave a
PCR product of 173 bp and fragments of 125 and 48
bp after digestion with HinfI.
The MTHFR polymorphism was found in every pop-
ulation tested. Unlike other mutations, such as factor V
Leiden (Rees et al. 1995), Dccr5 (Martinson et al. 1997),
and the HLA-H C282Y and H63D hemochromatosis
mutations (Merryweather-Clarke et al. 1997), which are
common only in Europe, the C677T mutation has a
relatively high frequency throughout the world.
The prevalence of the C677T mutation is lowest in
Africa (6.6%) compared with Europe and Asia, although
there are unexpected findings such as 44.9% in an in-
digenous Brazilian population and 4.5% in a group of
Sri Lankans. All of the populations in this study were
in Hardy-Weinberg equilibrium.
Both myocardial infarction (Murray and Lopez 1996)
and neural tube defects (Sever 1982) are believed to be
more prevalent in Europeans than in Africans. In de-
veloped countries where most people are of European
origin, the incidence of myocardial infarction is 15 times
greater than in sub-Saharan Africa, and the prevalence
rate for neural tube defects in whites is 1.5 times higher
than in blacks in U.S. populations. Although environ-
mental factors and other genetic factors clearly play an
important role, the geographical pattern of the C677T
allele frequency supports the hypothesis that it is a risk
factor for vascular disease and neural tube defects.
The high frequency of the C677Tmutationworldwide
is surprising if homozygotes have an increased risk of
disease. One possible explanation is that either hetero-
zygous or homozygous mutant genotypes may, in certain
circumstances, have a selective advantage over normal
individuals. Two such theories have been suggested: a
decreased risk of C677T homozygotes for colon cancer
(Chen et al. 1996) and a beneficial effect to heterozygotes
during times of starvation (Engbersen et al. 1995). In
the second hypothesis, the thermolabile form ofMTHFR
is believed to decrease homocysteine remethylation so
that the 1-carbon moieties of derivatives remain avail-
able for the vital synthesis of purines and thymidine.
The increased incidence of disease caused by the
C677T mutation may only have been mildly deleterious
to human populations. This could allow the C677T mu-
tation to behave as an effectively neutral polymorphism
so that demographic effects such as genetic drift could
outweigh slight negative selection. Populations that had
high frequencies of the C677T mutation and have been
small in the past would be most susceptible to this effect
(Thompson and Neel 1997).
